Preclinical News and Research

RSS
Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

9 Nov 2010
Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

9 Nov 2010
Merrimack receives $2.44 million under QTDP program to support cancer research

Merrimack receives $2.44 million under QTDP program to support cancer research

9 Nov 2010
EpiCept third quarter net loss decreases to $3.2 million

EpiCept third quarter net loss decreases to $3.2 million

9 Nov 2010
Soy-based drug could prevent prostate cancer metastasis

Soy-based drug could prevent prostate cancer metastasis

8 Nov 2010
Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

8 Nov 2010
TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

8 Nov 2010
CPEX third quarter revenues increase 17% to $5.8 million

CPEX third quarter revenues increase 17% to $5.8 million

8 Nov 2010
Gentium third quarter total revenues increase to EUR 5.91 million

Gentium third quarter total revenues increase to EUR 5.91 million

8 Nov 2010
XenoPort third quarter net loss decreases to $19.9 million

XenoPort third quarter net loss decreases to $19.9 million

8 Nov 2010
BioSpecifics Technologies third quarter net loss increases to $0.5 million

BioSpecifics Technologies third quarter net loss increases to $0.5 million

8 Nov 2010
Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

8 Nov 2010
GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

8 Nov 2010
Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen to present data on CHIKV vaccine at ASTMH meeting

8 Nov 2010
InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

8 Nov 2010
AiCuris to present data on AIC316 anti-HSV drug at Antivirals Congress

AiCuris to present data on AIC316 anti-HSV drug at Antivirals Congress

7 Nov 2010
Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

4 Nov 2010
Omeros third quarter net loss increases to $7.6 million

Omeros third quarter net loss increases to $7.6 million

4 Nov 2010
Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

4 Nov 2010
CaPre drug candidate effective in managing impaired glucose tolerance

CaPre drug candidate effective in managing impaired glucose tolerance

4 Nov 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback